Intellia Therapeutics Inc.

In News

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Yahoo Finance - May 11, 2026

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - GlobeNewswire

GlobeNewswire - May 11, 2026

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing - Intellia Therapeutics

Intellia Therapeutics - Apr 27, 2026

Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout

Kavout - May 11, 2026

Intellia Therapeutics (NTLA) posts Q1 loss but advances lonvo-z and nex-z - Stock Titan

Stock Titan - May 11, 2026

Intellia Therapeutics, Inc. Q1 2026: Revenue $15M, EPS $(0.81) — 10-Q Summary - TradingView

TradingView - May 11, 2026

Intellia Therapeutics Inc earnings beat by $0.10, revenue topped estimates - Investing.com

Investing.com - May 11, 2026

Intellia Therapeutics (NTLA) Reports Q1 Earnings Beat with Reven - GuruFocus

GuruFocus - May 11, 2026

Intellia Therapeutics Q1 Loss Narrows, Revenue Falls - marketscreener.com

marketscreener.com - May 11, 2026

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics - Apr 27, 2026

One-time CRISPR shot cuts HAE attacks 87% in Intellia trial - Stock Titan

Stock Titan - May 11, 2026

Intellia Therapeutics (NTLA) Sees Boost from ARK Invest's Recent ETF Purchases - GuruFocus

GuruFocus - May 11, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment